Glioblastoma (GBM) Brain Tumor Invasion and Consequences on Diagnosis, Clinical Strategies and Therapy

Dear Colleagues,

Glioblastoma is one of the most common primary brain tumors in adulthood and the most frequent glioma. To date, the best treatment for glioblastoma is surgery, followed by radiation therapy and chemotherapy with Temozolomide, however, considering the dismal prognosis related to its high malignancy even after this gold standard treatment, there are still many features to further clarify regarding the progression and recurrence of this disease. More specifically, recent fields of research regard the molecular behavior of Glioblastoma and the mechanism of healthy brain invasion and how the findings in this field affect clinical strategies.

The aim of this Special Issue of Neuroglia is to present a collection of articles that provides a current snapshot of the research in the Glioblastoma field. Manuscripts covering all aspects of research relating to Glioblastoma and the interaction between Glioblastoma and healthy brain tissues are welcome, including work from an applied perspective—such as novel diagnostics, use of new technologies, and innovations in the treatment of Glioblastoma—through to more fundamental questions relating to the biology of the disease and its pathogenesis, diffusion to surrounding tissues, and treatment.

Dr. Mauro Palmieri
Dr. Alessandro Pesce
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neuroglia is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.